Abbvie Inc.
A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
Granted 1.37M · Sold 839.2K
Granted 273.1K · Sold 181.7K
Granted 152.0K · Sold 124.0K
Granted 415.7K · Sold 157.2K
Granted 436.8K · Sold 112.0K
Granted 667.5K · Sold 579.8K
Granted 6.5K
Granted 139.9K
Granted 368.3K · Sold 222.2K
Granted 92.3K · Sold 37.3K
Granted 6.5K
Granted 39.8K
Granted 5.4K
Granted 131.7K · Sold 71.9K
Granted 6.5K · Sold 78.1K
Granted 142.6K · Sold 47.7K
Granted 5.4K
Granted 61.2K · Sold 30.4K
Granted 6.5K
Granted 6.5K
Granted 35.7K · Sold 30.9K
Granted 6.5K
Granted 6.5K
Granted 158.8K · Sold 121.4K
Granted 6.5K
Granted 2.5K
Granted 38.5K · Sold 25.9K
Granted 393.2K · Sold 290.1K
Granted 2.3K
Granted 3.6K
Granted 3.6K
Granted 6.1K · Sold 5.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gonzalez Richard ADirector · 43 transactions | -29.3% | 386.5Kas of Mar 2025 | 1.37M | — | 839.2K |
| Schumacher Laura JVice Chairman · 11 transactions | +15.8% | 248.0Kas of Feb 2022 | 273.1K | — | 181.7K |
| Gosebruch Henry OEVP, Chief Strategy Officer · 16 transactions | — | 246.5Kas of May 2022 | 152.0K | — | 124.0K |
| Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER · 38 transactions | +66.9% | 204.4K | 415.7K | — | 157.2K |
| Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Director · 32 transactions | +371.9% | 178.7K | 436.8K | — | 112.0K |
| Severino MichaelVice Chairman · 36 transactions | +46.5% | 152.1Kas of May 2022 | 667.5K | — | 579.8K |
| Freyman Thomas CDirector · 5 transactions | — | 133.8K | 6.5K | — | — |
| Hudson Thomas JSVP, CSO, GLOBAL RESEARCH · 15 transactions | +265.2% | 107.3Kas of Feb 2024 | 139.9K | — | — |
| Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER · 43 transactions | +61.6% | 84.5K | 368.3K | — | 222.2K |
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER · 19 transactions | +391.3% | 74.4K | 92.3K | — | 37.3K |
| Rapp Edward JDirector · 5 transactions | +50.1% | 56.4K | 6.5K | — | — |
| Thakkar RoopalEVP, R&D and CSO · 15 transactions | — | 55.4K | 39.8K | — | — |
| Tilton Glenn FDirector · 4 transactions | +11.6% | 51.9Kas of May 2025 | 5.4K | — | — |
| Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS · 28 transactions | +257.6% | 41.5Kas of Apr 2023 | 131.7K | — | 71.9K |
| Austin Roxanne SDirector · 10 transactions | -67.3% | 39.6K | 6.5K | — | 78.1K |
| Reents Scott TEVP, CHIEF FINANCIAL OFFICER · 25 transactions | — | 38.8K | 142.6K | — | 47.7K |
| Alpern Robert JDirector · 5 transactions | +18.3% | 35.6Kas of May 2025 | 5.4K | — | — |
| Durkin Brian LVP, CONTROLLER · 15 transactions | +57% | 33.1Kas of Feb 2023 | 61.2K | — | 30.4K |
| Waddell Frederick HDirector · 5 transactions | +27.6% | 30.1K | 6.5K | — | — |
| Burnside William H.L.Director · 5 transactions | +30.2% | 28.1K | 6.5K | — | — |
| Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH · 24 transactions | -45.1% | 28.0Kas of May 2023 | 35.7K | — | 30.9K |
| Hart Brett JDirector · 5 transactions | +46.3% | 20.6K | 6.5K | — | — |
| Meyer Melody BDirector · 5 transactions | +58.7% | 17.6K | 6.5K | — | — |
| Siatis Perry CEVP, GC AND SECRETARY · 51 transactions | — | 17.5K | 158.8K | — | 121.4K |
| Roberts Rebecca BDirector · 5 transactions | +78.2% | 14.8K | 6.5K | — | — |
| Crum Demetris DEVP, CHIEF HR OFFICER · 3 transactions | — | 7.9K | 2.5K | — | — |
| Buckbee Kevin KSVP, CONTROLLER · 17 transactions | — | 7.8Kas of Feb 2025 | 38.5K | — | 25.9K |
| Richmond Timothy J.EVP, CHIEF HR OFFICER · 46 transactions | — | 6.1Kas of Mar 2025 | 393.2K | — | 290.1K |
| Falk Thomas JDirector · 2 transactions | — | 5.3K | 2.3K | — | — |
| Davis Jennifer L.Director · 3 transactions | — | 3.6K | 3.6K | — | — |
| Quaggin Susan EDirector · 3 transactions | — | 3.6K | 3.6K | — | — |
| Purdue David RyanSVP, Controller · 6 transactions | — | 1.1K | 6.1K | — | 5.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -2.96M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.